Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Retrospective Cohort Study Investigating Bedaquiline and Linezolid for the Operational Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in a High Burden HIV Setting

Next Previous
X
Search
Trial Profile

A Retrospective Cohort Study Investigating Bedaquiline and Linezolid for the Operational Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in a High Burden HIV Setting

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bedaquiline (Primary) ; Linezolid (Primary)
  • Indications Tuberculosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BLIX

    • Most Recent Events

    • 20 May 2020 Results (N=116 bedaquiline-linezolid cohort + 80 from historical cohort), comparing rates of adverse events in DR-TB HIV patients receiving bedaquiline-linezolid with ART compared to previous regimens, presented at the 116th International Conference of the American Thoracic Society
    • 13 Jul 2017 New trial record
    • 24 May 2017 Results (n=153) presented at the 113th International Conference of the American Thoracic Society.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top